Abiopharma

🔍 Gold Daniel Allen (Executive)

Company: Roivant Sciences Ltd. (ROIV)

Report Date: 2026-06-26

Detailed Transactions and Holdings:

• Sold 300,783 shares of Common Shares at $33.92 per share (Direct)
  Date: 2026-06-26 | Code: S | equity_swap_involved: false | shares_owned_after: 14,826,546.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 325,000 shares of Common Shares at $34.07 per share (Direct)
  Date: 2026-06-26 | Code: S | equity_swap_involved: false | shares_owned_after: 14,501,546.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 200,000 shares of Common Shares at $34.44 per share (Direct)
  Date: 2026-06-29 | Code: S | equity_swap_involved: false | shares_owned_after: 14,301,546.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 600,000 shares of Common Shares at $34.59 per share (Direct)
  Date: 2026-06-29 | Code: S | equity_swap_involved: false | shares_owned_after: 13,701,546.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 12,380 shares of Common Shares at $35.28 per share (Direct)
  Date: 2026-06-30 | Code: S | equity_swap_involved: false | shares_owned_after: 13,689,166.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: The reporting person is one of three directors of QVT Financial Investment Cayman Ltd. ("QVT FIC"), sharing voting and investment control over the Common Shares held directly by QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose.